Asthika Goonewardene
Stock Analyst at Truist Securities
(1.84)
# 3,128
Out of 5,180 analysts
89
Total ratings
32.08%
Success rate
-8.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Hold | $134 → $120 | $114.82 | +4.51% | 6 | Feb 24, 2026 | |
| ZYME Zymeworks | Initiates: Buy | $40 | $25.04 | +59.74% | 1 | Dec 17, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $43 | $23.07 | +86.39% | 1 | Nov 25, 2025 | |
| GMAB Genmab | Reiterates: Buy | $49 → $48 | $26.83 | +78.90% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Reiterates: Buy | $127 → $145 | $139.37 | +4.04% | 3 | Nov 3, 2025 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $32 → $39 | $21.60 | +80.56% | 2 | Oct 7, 2025 | |
| JANX Janux Therapeutics | Initiates: Buy | $100 | $13.90 | +619.42% | 1 | Sep 10, 2025 | |
| RVMD Revolution Medicines | Initiates: Buy | $99 | $97.25 | +1.80% | 1 | Sep 5, 2025 | |
| EXEL Exelixis | Maintains: Buy | $56 → $49 | $42.89 | +14.25% | 11 | Jul 29, 2025 | |
| BNTX BioNTech SE | Reiterates: Buy | $151 → $155 | $88.88 | +74.39% | 3 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $88 → $71 | $18.09 | +292.48% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $10 | $2.44 | +309.84% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $1.38 | +624.64% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $15 | $3.51 | +327.35% | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $18.96 | +84.60% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $150 | $24.91 | +502.17% | 6 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $2.13 | +87.79% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $1.90 | +900.00% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $432 | $6.81 | +6,243.61% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $8.26 | +1,352.78% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $1.33 | +4,411.28% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $228 → $180 | $10.68 | +1,585.39% | 4 | Aug 23, 2022 |
Arcellx
Feb 24, 2026
Downgrades: Hold
Price Target: $134 → $120
Current: $114.82
Upside: +4.51%
Zymeworks
Dec 17, 2025
Initiates: Buy
Price Target: $40
Current: $25.04
Upside: +59.74%
ArriVent BioPharma
Nov 25, 2025
Initiates: Buy
Price Target: $43
Current: $23.07
Upside: +86.39%
Genmab
Nov 7, 2025
Reiterates: Buy
Price Target: $49 → $48
Current: $26.83
Upside: +78.90%
Gilead Sciences
Nov 3, 2025
Reiterates: Buy
Price Target: $127 → $145
Current: $139.37
Upside: +4.04%
Arcus Biosciences
Oct 7, 2025
Reiterates: Buy
Price Target: $32 → $39
Current: $21.60
Upside: +80.56%
Janux Therapeutics
Sep 10, 2025
Initiates: Buy
Price Target: $100
Current: $13.90
Upside: +619.42%
Revolution Medicines
Sep 5, 2025
Initiates: Buy
Price Target: $99
Current: $97.25
Upside: +1.80%
Exelixis
Jul 29, 2025
Maintains: Buy
Price Target: $56 → $49
Current: $42.89
Upside: +14.25%
BioNTech SE
Jun 3, 2025
Reiterates: Buy
Price Target: $151 → $155
Current: $88.88
Upside: +74.39%
May 14, 2025
Maintains: Buy
Price Target: $88 → $71
Current: $18.09
Upside: +292.48%
May 14, 2025
Maintains: Buy
Price Target: $14 → $10
Current: $2.44
Upside: +309.84%
Apr 1, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $1.38
Upside: +624.64%
Mar 3, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $3.51
Upside: +327.35%
Jan 8, 2025
Initiates: Buy
Price Target: $35
Current: $18.96
Upside: +84.60%
Aug 16, 2024
Maintains: Buy
Price Target: $180 → $150
Current: $24.91
Upside: +502.17%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $2.13
Upside: +87.79%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $1.90
Upside: +900.00%
Sep 6, 2023
Reiterates: Buy
Price Target: $432
Current: $6.81
Upside: +6,243.61%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $8.26
Upside: +1,352.78%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $1.33
Upside: +4,411.28%
Aug 23, 2022
Maintains: Buy
Price Target: $228 → $180
Current: $10.68
Upside: +1,585.39%